EMEA-001075-PIP04-15-M06 - paediatric investigation plan

Romosozumab
PIPHuman

Key facts

Invented name
Evenity
Active Substance
Romosozumab
Therapeutic area
Endocrinology-Gynaecology-Fertility-Metabolism
Decision number
P/0171/2023
PIP number
EMEA-001075-PIP04-15-M06
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of osteoporosis
Route(s) of administration
Subcutaneous use
Contact for public enquiries

UCB Pharma S.A.

E-mail: UCBCares.UK@ucb.com
Tel: +44 (0)1753777100

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

Share this page